What kind of data does Eastern Europe Impact provide on Ambu?

Eastern Europe Impact publishes verified intelligence on Ambu's Russia status: current operating posture, sources (including the KSE LeaveRussia project), status history since 2022, sanctions-list matches, and linked events. Each profile is risk information for compliance and due diligence — not legal advice.

How can Eastern Europe Impact data on Ambu help my business?

Use the Ambu profile to check counterparties, suppliers and customers for Russia exposure, sanctions proximity and recent events before you contract, ship or invest. Watchlists alert you if the status or designations change.

How do we verify the information on Ambu?

We compile public reporting, company statements and the KSE LeaveRussia dataset, then label uncertainty. Status is not a legal determination — verify against primary filings and counsel before acting. Corrections go to corrections@easterneuropeimpact.com.

How much does Eastern Europe Impact cost?

The company checker is free. A 7-day Pro trial (no credit card) unlocks live Daily Impact Briefs, full event profiles and watchlists. After the trial, Individual is €19/month; Professional and Business add exposure maps, sanctions entity pages and API access. See /pricing.

Ambu: Russia Operations Status & Business Impact

Denmark · Pharma & Healthcare

LeaveRussia detail: Exit Completed

Exited Russia

Ambu, or officially Ambu A/S, is a Danish company that develops, produces and markets single-use endoscopy solutions, diagnostic and life-supporting equipment to hospitals, private practices, and rescue services. It was founded in Denmark in 1937, as Testa Laboratorium, by German engineer Holger Hesse.

Status last verified 03/08/2026Source checked 30/09/2025Company website ↗LeaveRussia profile ↗

Decision trail

Decision date 10/07/2025 · Reference ↗

It’s a legal battle for pharmaceutical company Ambu to liquidate its subsidiary in Russia, but CEO Britt Meelby Jensen remains confident that it will be accomplished before the New Year (2024). "Ambu is in the process of formally liquidating our Russian subsidiary. We did not sell or promote any products in Russia during the 2023/24 financial year, and we have no plans to do so in the future," the company said in its annual report. 10.07.2025: The legal entity AMBU LLC was liquidated.

Local stats (LeaveRussia)

Staff(RF), 2021

Status history since 2022

03/08/2026 — exited · Imported from KSE LeaveRussia

Possible sanctions matches

Name-based matches against EU/US/UK lists — verify identity before drawing conclusions.

Exposure profile

Get alerts if this company's Russia status changes

7-day Pro trial includes watchlists for companies you track. No credit card. Full exposure maps are on Professional after the trial.

Start 7-day Pro trial

Recent events mentioning Ambu

humanitarianukrainelow impact18 Aug

Reports of ambulance damaged and driver injured due to repeated explosions

X reports that an ambulance was damaged and its driver injured as a result of repeated explosions. The details are not independently verified.

Confidence: 40/100

humanitarianukrainelow impact10 Aug

Kliczko reports ambulance call in Shevchenkivskyi district of Kyiv — not independently verified

Kliczko has reported an ambulance call in the Shevchenkivskyi district of Kyiv. Further details are not available.

Confidence: 48/100

politicaleumedium impact10 Aug

Minister Joller defends ambulance reform plans for better emergency care

Social Affairs Minister Karmen Joller defended Estonia's ambulance reform plans from critics. The changes are aimed at improving response times and quality of care.

Confidence: 67/100

Geopolitical context and sanctions impact

Ambu is a Pharma & Healthcare company based in Denmark. Current Russia status in our dataset is exited: an announced exit should still be checked against local filings, remaining subsidiaries and any sanctions-list matches. Eastern Europe Impact translates those facts into business consequences — sanctions screening, supply-chain exposure and reconstruction-side opportunity — with transparent confidence labels rather than speculation.

Risk assessment and how to use this profile

Start with the status badge and decision trail, then check possible sanctions matches and recent events mentioning Ambu. A 7-day Pro trial adds watchlists so you are notified if Russia status, designations or linked events change. Full exposure maps (energy, transport, commodities) are on Professional. This page is risk information, not legal or investment advice.

Questions about Ambu

What kind of data does Eastern Europe Impact provide on Ambu?: Eastern Europe Impact publishes verified intelligence on Ambu's Russia status: current operating posture, sources (including the KSE LeaveRussia project), status history since 2022, sanctions-list matches, and linked events. Each profile is risk information for compliance and due diligence — not legal advice.
How can Eastern Europe Impact data on Ambu help my business?: Use the Ambu profile to check counterparties, suppliers and customers for Russia exposure, sanctions proximity and recent events before you contract, ship or invest. Watchlists alert you if the status or designations change.
How do we verify the information on Ambu?: We compile public reporting, company statements and the KSE LeaveRussia dataset, then label uncertainty. Status is not a legal determination — verify against primary filings and counsel before acting. Corrections go to corrections@easterneuropeimpact.com.
How much does Eastern Europe Impact cost?: The company checker is free. A 7-day Pro trial (no credit card) unlocks live Daily Impact Briefs, full event profiles and watchlists. After the trial, Individual is €19/month; Professional and Business add exposure maps, sanctions entity pages and API access. See /pricing.